<DOC>
	<DOCNO>NCT00842452</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , topotecan , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This phase I trial study side effect best dose topotecan treating patient gynecologic cancer remove surgery .</brief_summary>
	<brief_title>Topotecan Treating Patients With Gynecologic Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To establish maximum tolerate dose ( MTD ) oral topotecan hydrochloride patient unresectable gynecologic malignancy . - To determine safety tolerability drug patient . - To obtain pharmacokinetic data ass plasma concentration drug administer MTD . Secondary - To explore response patient treated drug . OUTLINE : Patients receive oral topotecan hydrochloride day 1 , 8 , 15 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients treat maximum tolerated dose undergo blood sample collection periodically day 1 course 1 pharmacokinetic study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Vulvar Neoplasms</mesh_term>
	<mesh_term>Vaginal Neoplasms</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically* cytologically confirm unresectable gynecologic malignancy standard curative palliative care available All tumor type allow NOTE : *Histologic confirmation recurrence require Measurable nonmeasurable disease If CT scan use evaluate measurable disease , lesion must clearly define ≥ 10 mm spiral CT scan No `` borderline tumor '' tumor low malignant potential PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Life expectancy ≥ 12 week ANC ≥ 1,500/μL Platelet count ≥ 100,000/μL Hemoglobin ≥ 9 g/dL Creatinine ≤ 1.5 time upper limit normal ( ULN ) Creatinine clearance ≥ 60 mL/min AST/ALT ≤ 2.5 time ULN ( &lt; 5 time ULN liver metastasis present ) Alkaline phosphatase ≤ 2.5 time ULN ( &lt; 5 time ULN liver metastasis present ) Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Adequate intestinal function ( i.e. , gastrostomy tube requirement IV hydration nutritional support ) No severe gastrointestinal bleeding intestinal obstruction No condition would affect gastrointestinal absorption motility No septicemia , severe infection , acute hepatitis No malignancy require chemotherapy radiotherapy within past 5 year , except skin cancer No concurrent severe medical problem unrelated malignancy would significantly limit full compliance study , expose patient extreme risk , decrease life expectancy PRIOR CONCURRENT THERAPY : At least 28 day since prior investigational drug ( include cytotoxic drug ) At least 4 week since prior chemotherapy , radiotherapy , biologic therapy , surgery recover No 3 prior chemotherapy regimens No prior topotecan hydrochloride camptothecin analogs No prior radiotherapy &gt; 25 % bone marrow No concurrent chemotherapy , radiotherapy , biologic therapy , immunotherapy , hormonal therapy cancer No concurrent administration follow : Pglycoprotein ( ABCB1 , Pgp , MDR1 ) inhibitors inducer Breast cancerresistant protein ( ABCG2 , BCRP , MXR ) inhibitor inducers No concurrent chronic H2 antagonist , proton pump inhibitor , antacid gastritis , gastroesophageal reflux disease , gastric duodenal ulcer Intermittent antacid therapy allow provide give ≥ 6 hour prior ≥ 90 minute study drug administration</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage III ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>stage III endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>stage III uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent vaginal cancer</keyword>
	<keyword>stage III vaginal cancer</keyword>
	<keyword>stage IVA vaginal cancer</keyword>
	<keyword>stage IVB vaginal cancer</keyword>
	<keyword>recurrent vulvar cancer</keyword>
	<keyword>stage III vulvar cancer</keyword>
	<keyword>stage IV vulvar cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>ovarian stromal cancer</keyword>
</DOC>